peptidechats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Exenatide

Also known as: Byetta, Bydureon, exendin-4 synthetic analog, AC-2993, exenatide extended-release, exenatide QW, exenatide LAR

GLP-1 receptor agonist; incretin mimetic; synthetic exendin-4 analog; antihyperglycemic agent

Research chemicalLast updated: October 10, 2026Based on 4 peer-reviewed studiesPreclinical data only — no human trials
Ask about Exenatide in chat →

What it is

Exenatide (Byetta, Bydureon) is a diabetes medication derived from a peptide found in Gila monster saliva that helps the body control blood sugar after meals. It stimulates insulin release only when glucose is elevated, suppresses glucagon, slows digestion, and reduces appetite — making it useful for type 2 diabetes management and often producing meaningful weight loss.

The scientific side

Exenatide is described as a synthetic analog of exendin-4, a 39-amino acid peptide isolated from the salivary secretions of the Gila monster (Heloderma suspectum), sharing approximately 53% amino acid sequence identity with human GLP-1 (glucagon-like peptide-1). Unlike native GLP-1, exenatide resists cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4), conferring a plasma half-life of approximately 2.4 hours following subcutaneous injection compared to less than 2 minutes for endogenous GLP-1. Exenatide acts as a full agonist at the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed on pancreatic beta cells, alpha cells, gastric tissue, hypothalamus, brainstem, and kidney. Through GLP-1R activation, exenatide exerts four primary pharmacological actions. First, it stimulates insulin secretion in a strictly glucose-dependent manner — insulin release occurs only when plasma glucose is elevated, substantially reducing the risk of fasting hypoglycemia compared to sulfonylureas. Second, it suppresses postprandial glucagon secretion from pancreatic alpha cells, correcting the paradoxically elevated glucagon response seen in type 2 diabetes after meals, which contributes significantly to postmeal hyperglycemia. Third, it slows gastric emptying, attenuating the rate of nutrient absorption and blunting postprandial glucose excursions. Fourth, it acts centrally on hypothalamic satiety circuits and the area postrema to reduce appetite and food intake, producing progressive body weight reductions in clinical trials. Additional investigated mechanisms include neural effects on visual cortex processing (PMID 30974038), effects on gut-kidney signaling pathways (PMID 42851342), and potential neuroinflammatory modulation relevant to CNS disease (PMID 42848200). The once-weekly Bydureon formulation uses poly(D,L-lactide-co-glycolide) microsphere technology to achieve sustained drug release from a single subcutaneous depot injection, maintaining therapeutic plasma concentrations throughout the week without the twice-daily dosing burden of Byetta.

Class: GLP-1 receptor agonist; incretin mimetic; synthetic exendin-4 analog; antihyperglycemic agent

Administration & storage

Administration
Subcutaneous injection into the abdomenthighor upper armByetta: administered with a separate pen needle (not included); needle length 4–8 mm typicalBydureon: use only the provided needle; inject immediately after reconstitutionDo not inject intravenously or intramuscularlyRotate injection sites with each dose to reduce lipohypertrophy
Storage
Byetta: refrigerate unused pens at 2–8°C (36–46°F); do not freeze; in-use pen may be kept at room temperature ≤25°C for up to 30 days; protect from heat and light. Bydureon: refrigerate at 2–8°C; may be kept at room temperature ≤25°C for up to 4 weeks; do not freeze; protect from light.
Cautions
CONTRAINDICATED in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — rodent carcinogenicity data; human risk not established but label carries warning.,CONTRAINDICATED in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease; exenatide is cleared via renal filtration and degradation.,Acute pancreatitis has been reported in post-marketing surveillance; FDA received 36 presumed pancreatitis cases early in post-marketing period. Discontinue promptly if pancreatitis suspected; do not restart.,Nausea is the most common adverse effect (reported in ~40–50% of patients); typically transient, peaks in weeks 1–4, and diminishes with continued use. Starting at 5 mcg BID reduces GI intolerance.,Risk of hypoglycemia increased when used with sulfonylureas; consider reducing sulfonylurea dose when initiating exenatide. Hypoglycemia risk with metformin or thiazolidinediones alone is low.,Do not use in type 1 diabetes or for treatment of diabetic ketoacidosis.,Bydureon injection-site nodules (subcutaneous lumps) are common (up to 17% of patients) due to microsphere depot; usually resolve over weeks; rotate sites.

Legal & regulatory status

US FDA

FDA-approved (NDA) as Byetta (exenatide injection, 5 mcg and 10 mcg twice-daily) for type 2 diabetes mellitus as adjunct to diet and exercise; approved April 2005. Also approved as Bydureon (exenatide extended-release…

WADA

Exenatide is not listed on the current WADA Prohibited List. It is a prescription therapeutic peptide used exclusively for diabetes management with no established performance-enhancing mechanism in healthy athletes.…

Health Canada

Byetta (exenatide) is approved by Health Canada as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes, used in combination with metformin and/or a sulfonylurea when these agents do not…